Donald Hammer, M.D.
| Appointed: |
1998 |
| Gender: |
Male |
| Languages: |
English |
Cardiovascular Medicine
Biographical Sketch
Dr. Donald Hammer is Director of Cardiology Surgical Services and a staff cardiologist in the Section of Clinical Cardiology, Department of Cardiovascular Medicine, at Cleveland Clinic Heart and Vascular Institute. He is board certified in internal medicine and cardiology. Dr. Hammer's specialty interests are ischemic heart disease and perioperative cardiac management.
Dr. Hammer graduated summa cum laude from Case Western Reserve University (Phi Beta Kappa) with an undergraduate degree in chemistry. He received his medical degree from The Ohio State University College of Medicine, in Columbus, Ohio, where he was inducted in the Alpha Omega Alpha honor society. He completed his clinical internship and residency in internal medicine at The Ohio State University Hospitals, where he went on to receive a fellowship in cardiology.
Dr. Hammer served 10 years in the United States Naval Corps and retired as a Lieutenant Commander, U.S. Naval Medical Corps. He has had multiple academic appointments, which include Clinical Instructor in Internal Medicine at The Ohio State University Hospitals; Director of Education, Internal Medicine at the Naval Regional Medical Center at Camp Pendleton, CA; Assistant Clinical Professor of Medicine and Associate Medical Director of the Cardiac Transplantation Program at The Ohio State University Hospitals; Education Coordinator for Cardiology at Wright State University in Dayton, OH, where he was also Director of the Cardiology Fellowship Training Program; Director of the Echocardiography Laboratory and Chairman of the Cardiology Research Panel at Good Samaritan Hospital in Dayton, among others. In 1998, Dr. Hammer was appointed to the Cleveland Clinic Foundation as Director of Cardiology Surgical Services.
Dr. Hammer has long been involved in clinical studies on his specialty interests and heart related issues. His post basic research endeavors included high-energy phosphate analysis in dilated cardiomyopathy and CHF. He currently is the principal investigator on a retrospective comparison of second and third generation beta blockers and post-operative atrial fibrillation prophylaxis, and is a co-investigator on the safety and efficacy in low molecular weight heparin in selected patients post open heart surgery. Dr. Hammer has participated in many other clinical trials including the QUIET STUDY and in the GUSTO trials.
He has presented his research findings and addressed his specialty interests at many national conferences and symposia. He is the author or co-author of articles related to his work in leading publications, including Circulation, Heart, and the New England Journal of Medicine, to name a few. In addition, he has co-authored a chapter on endogenous inotrope in a medical textbook on Cardiotonic Drugs.
Dr. Hammer is Fellow in the American College of Cardiology and a member of the American Medical Association, the American Society of Echocardiography and the Medical Society of Northeastern Ohio.
Education & Fellowships
| Medical School: | The Ohio State University College of Medicine and Public Health, Columbus, OH |
|
| Internship: | The Ohio State University Hospitals, Internal Medicine, Columbus, OH |
| Residency: | The Ohio State University Hospitals, Internal Medicine, Columbus, OH |
| Fellowship: | The Ohio State University Hospitals, Cardiology, Columbus, OH |
| Other Education: | (Undergraduate) Case Western Reserve University, Cleveland, OH |
Certifications
Cardiovascular Disease
Internal Medicine
Specialty Interests
Ischemic heart disease, perioperative cardiac management.
Specializes in Diseases and Conditions
Industry Relationships
Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical education about recent trends. The collaborations are reviewed as part of the Cleveland Clinic’s procedures. The Cleveland Clinic publicly discloses payments to its physicians and scientists for speaking and consulting of $5,000 or more per year, and any equity, royalties, and fiduciary relationships in companies with which they collaborate. The Cleveland Clinic requires its doctors to approve the public disclosures of their scientific collaborations with industry. As of 10/24/2008 the review process regarding Dr. Hammer’s disclosure had not been completed. Patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by the Cleveland Clinic. To learn more about the Cleveland Clinic’s policies on collaborations with industry and innovation management, go to our
Integrity in Innovation page.
( † Disclaimer: This search is powered by PubMed, a service of the U.S.
National Library of Medicine. PubMed is a third-party website with no
affiliation with Cleveland Clinic.)
